Jixing Pharmaceuticals will develop investigational drug globally
SHANGHAI, China I January 11, 2024 I Ji Xing Pharmaceuticals (“JIXING”), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced today the acquisition of BIIB131 from Biogen, for global clinical development.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
In the prior Phase 2 clinical trial conducted in Japan, patients treated with BIIB 131 had significantly improved clinical outcomes (proportion of patients with no or minimal neurological deficits) at 90 days, compared to placebo. This was further supported by safety and angiographic findings.
“Stroke is a serious threat to global health. BIIB 131 represents a potential breakthrough for a critical condition (AIS) that has not seen any meaningful pharmacologic innovation for almost 30 years. We hope to prove that BIIB 131 will significantly improve clinical outcomes for AIS patients around the world”, said Sandy Mou, Board Executive Director and Chief Executive Officer of JIXING. “This acquisition will not only enrich JIXING’s pipeline, but also accelerate the execution of our globalization strategy.”
“We believe that BIIB131 has the potential to change the way we treat acute strokes,” said Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP. “We would like to thank Biogen and TMS for their ongoing partnership and for their efforts to bring this asset to where it is today.”
Under the terms of the agreement, JIXING will acquire the program for an undisclosed upfront with potential milestones and royalties on global sales.
JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients with serious and life-threatening diseases in China and around the world. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients.
JIXING’s cardiovascular portfolio includes 3 assets in late-stage clinical development (aficamten, etripamil, omecamtiv mecarbil) and 1 in pre-clinical stage (JX09). JIXING’s ophthalmology portfolio includes 4 assets in late-stage clinical development (varenicline solution nasal spray/US brand name TYRVAYA, OC-02 nasal spray, JX06/LNZ100, JX07/LNZ101) and 1 asset in pre-clinical stage (JX08). For further information about JIXING, please visit www.jixing.com .
SOURCE: Ji Xing Pharmaceuticals
Post Views: 734
Jixing Pharmaceuticals will develop investigational drug globally
SHANGHAI, China I January 11, 2024 I Ji Xing Pharmaceuticals (“JIXING”), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced today the acquisition of BIIB131 from Biogen, for global clinical development.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
In the prior Phase 2 clinical trial conducted in Japan, patients treated with BIIB 131 had significantly improved clinical outcomes (proportion of patients with no or minimal neurological deficits) at 90 days, compared to placebo. This was further supported by safety and angiographic findings.
“Stroke is a serious threat to global health. BIIB 131 represents a potential breakthrough for a critical condition (AIS) that has not seen any meaningful pharmacologic innovation for almost 30 years. We hope to prove that BIIB 131 will significantly improve clinical outcomes for AIS patients around the world”, said Sandy Mou, Board Executive Director and Chief Executive Officer of JIXING. “This acquisition will not only enrich JIXING’s pipeline, but also accelerate the execution of our globalization strategy.”
“We believe that BIIB131 has the potential to change the way we treat acute strokes,” said Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP. “We would like to thank Biogen and TMS for their ongoing partnership and for their efforts to bring this asset to where it is today.”
Under the terms of the agreement, JIXING will acquire the program for an undisclosed upfront with potential milestones and royalties on global sales.
JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients with serious and life-threatening diseases in China and around the world. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients.
JIXING’s cardiovascular portfolio includes 3 assets in late-stage clinical development (aficamten, etripamil, omecamtiv mecarbil) and 1 in pre-clinical stage (JX09). JIXING’s ophthalmology portfolio includes 4 assets in late-stage clinical development (varenicline solution nasal spray/US brand name TYRVAYA, OC-02 nasal spray, JX06/LNZ100, JX07/LNZ101) and 1 asset in pre-clinical stage (JX08). For further information about JIXING, please visit www.jixing.com .
SOURCE: Ji Xing Pharmaceuticals
Post Views: 734
